Alessandro Levis
Research Subjects
Alessandro Levis has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
D. Gioia
Hematology; Ospedale Alessandria; Alessandria Italy
7 shared publicationsF. Salvi
Hematology; Ospedale Alessandria; Alessandria Italy
6 shared publicationsD. Ferrero
5 shared publicationsM. Lunghi
5 shared publicationsB. Allione
4 shared publicationsD. Cilloni
4 shared publications
Latest Publications
- Open Access
- 7 June 2017
- Published by Wiley in Hematological Oncology
- Vol. 35, 38
CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)
- 7 June 2017
- Published by Wiley in Hematological Oncology
- Vol. 35, 38
Open AccessCLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)
- 1 April 2015
- Published by Elsevier in Leukemia Research
- Vol. 39, S84-S85
166 TARGETED SEQUENCING ANALYSIS OF COMMONLY MUTATED GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA USING NGS: IMPACT AND CLINICAL IMPLICATIONS
- 1 April 2015
- Published by Elsevier in Leukemia Research
- Vol. 39, S84-S85
166 TARGETED SEQUENCING ANALYSIS OF COMMONLY MUTATED GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA USING NGS: IMPACT AND CLINICAL IMPLICATIONS
- 1 May 2013
- Published by Elsevier in Leukemia Research
- Vol. 37, S17
O-018 Efficacy of decitabine in advanced chronic myelomonocytic leukemia (CMML) patients
- 1 May 2013
- Published by Elsevier in Leukemia Research
- Vol. 37, S17
O-018 Efficacy of decitabine in advanced chronic myelomonocytic leukemia (CMML) patients
- Open Access
- 10 September 2012
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 53
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study
Arsenic Trioxide (ATO) is effective in about 20% of patients with myelodysplasia (MDS); its mechanisms of action have already been evaluated in vitro, but the in vivo activity is still not fully understood. Since ATO induces apoptosis in in vitro models, we compared the expression of 93 apoptotic genes in patients’ bone marrow before and after ATO treatment. For this analysis, we selected 12 patients affected by MDS who received ATO in combination with Ascorbic Acid in the context of the Italian clinical trial NCT00803530, EudracT Number 2005-001321-28.
- 10 September 2012
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 53
Open AccessArsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study
Arsenic Trioxide (ATO) is effective in about 20% of patients with myelodysplasia (MDS); its mechanisms of action have already been evaluated in vitro, but the in vivo activity is still not fully understood. Since ATO induces apoptosis in in vitro models, we compared the expression of 93 apoptotic genes in patients’ bone marrow before and after ATO treatment. For this analysis, we selected 12 patients affected by MDS who received ATO in combination with Ascorbic Acid in the context of the Italian clinical trial NCT00803530, EudracT Number 2005-001321-28.
- Open Access
- 1 August 2012
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 44
Outcome of therapy-related myeloid neoplasms treated with azacitidine
Background: Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation. Methods: We retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of 6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor, 23 patients). Results: The overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1–6). Median overall survival (OS) was 21 months (range 1–53.6+) from AZA start. OS was significantly better in patients with less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was confirmed by the multivariate analysis. Conclusions: This study reports efficacy of AZA in the largest series of therapy-related MN patients treated with 5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the azacitidine era.
- 1 August 2012
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 44
Open AccessOutcome of therapy-related myeloid neoplasms treated with azacitidine
Background: Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation. Methods: We retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of 6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor, 23 patients). Results: The overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1–6). Median overall survival (OS) was 21 months (range 1–53.6+) from AZA start. OS was significantly better in patients with less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was confirmed by the multivariate analysis. Conclusions: This study reports efficacy of AZA in the largest series of therapy-related MN patients treated with 5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the azacitidine era.
- 31 May 2009
- Published by Elsevier in Leukemia Research
- Vol. 33, S108-S109
P087 Analysis of iron homeostasis and erythroid activity in a cohort of low-risk myelodysplastic patients
- 31 May 2009
- Published by Elsevier in Leukemia Research
- Vol. 33, S108-S109
P087 Analysis of iron homeostasis and erythroid activity in a cohort of low-risk myelodysplastic patients
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 8506
Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups
8506 Background: The availability of successful and tolerated salvage programs challenges the choice of more effective but more toxic regimens as preferred first-line treatments of chemosensitive tumors. In fact, a less toxic and more applicable initial therapy that can be effectively salvaged, might be a preferable strategy to a moderately more effective regime with a higher rate of toxic events and a lower rescue rate. We thus compared the rate of freedom-from-progression (FFP), freedom-from-second-progression (FF2P) and overall survival (OS) of patients with advanced HL treated according to two opposite strategies: ABVD first, versus BEACOPP first, plus high-dose salvage as pre- planned intended treatment for both arms. Methods: From March 2000 to March 2007, a total of 321 eligible patients with stage IIB/IV and/or ≥3 IPS (international-prognostic-score) HL were stratified and randomized; 166 patients received 6–8 cycles of ABVD, and 155 patients were treated with 4 cycles of BEACOPP escalated plus 4 cycles of BEACOPP standard. Responding patients received 30 Gy of radiotherapy to sites of initial bulky disease or of residual mass. For treatment failures the intent was to deliver re-induction chemotherapy followed by stem-cell supported BEAM, and up to 25 Gy of radiotherapy, as required. Results: Main patient characteristics and 3- year results (median observation 30 months, lead 85 months) are summarized in the table: Conclusions: A longer follow-up is necessary to account for late relapses and secondary tumors. Within these limits, the present study, by taking into account both first-line and second-line chemotherapy, helps defining a preferred therapeutic plan for advanced HL. In fact, BEACOPP-first scored a superior FFP in 16% of the patients, but showed a comparable FF2P and an identical OS rate, and was thus an overtreatment for the 71% already cured by ABVD-first. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 8506
Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups
8506 Background: The availability of successful and tolerated salvage programs challenges the choice of more effective but more toxic regimens as preferred first-line treatments of chemosensitive tumors. In fact, a less toxic and more applicable initial therapy that can be effectively salvaged, might be a preferable strategy to a moderately more effective regime with a higher rate of toxic events and a lower rescue rate. We thus compared the rate of freedom-from-progression (FFP), freedom-from-second-progression (FF2P) and overall survival (OS) of patients with advanced HL treated according to two opposite strategies: ABVD first, versus BEACOPP first, plus high-dose salvage as pre- planned intended treatment for both arms. Methods: From March 2000 to March 2007, a total of 321 eligible patients with stage IIB/IV and/or ≥3 IPS (international-prognostic-score) HL were stratified and randomized; 166 patients received 6–8 cycles of ABVD, and 155 patients were treated with 4 cycles of BEACOPP escalated plus 4 cycles of BEACOPP standard. Responding patients received 30 Gy of radiotherapy to sites of initial bulky disease or of residual mass. For treatment failures the intent was to deliver re-induction chemotherapy followed by stem-cell supported BEAM, and up to 25 Gy of radiotherapy, as required. Results: Main patient characteristics and 3- year results (median observation 30 months, lead 85 months) are summarized in the table: Conclusions: A longer follow-up is necessary to account for late relapses and secondary tumors. Within these limits, the present study, by taking into account both first-line and second-line chemotherapy, helps defining a preferred therapeutic plan for advanced HL. In fact, BEACOPP-first scored a superior FFP in 16% of the patients, but showed a comparable FF2P and an identical OS rate, and was thus an overtreatment for the 71% already cured by ABVD-first. No significant financial relationships to disclose.